IL-MOTOROLA-SOLUTIONS
27.10.2020 14:02:14 CET | Business Wire | Press release
A global pandemic, ever-increasing volumes of data to manage and greater demand to do more with limited resources - the world has never been more complex for public safety agencies.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201027005282/en/
Siloed systems and devices that don’t talk with each other can add to an already existing complexity. First responders need mission-critical technology that offers an intuitive and smart experience to respond effectively in the “heat of the moment,” as well as flexible tools that enable them to connect seamlessly with a broader ecosystem of technologies.
Motorola Solutions is launching its next-generation Terrestrial Trunked Radio (TETRA) device: the smart and powerful MXP600 , to meet the needs of public safety personnel today and well into the future. The lightweight yet highly rugged radio takes the proven capabilities of mission-critical voice communication to new levels and can collaborate with other solutions.
“Frontline professionals will always need their radio in high-stress situations to serve as their lifeline, but they also might require collaboration with other devices that they carry, including smartphones and body worn video cameras, without compromising the security or reliability of their radio voice communications,” said Mark Schmidl, senior vice president at Motorola Solutions.
“Instead of handling multiple devices simultaneously they can activate other devices through the one that feels most natural and intuitive to use in that situation. For example, if a police officer presses the emergency button in a life-threatening situation, the radio will in the future be able to automatically activate the body worn camera, without the officer needing to start the process separately. It's all about simplifying yet elevating key features of mission-critical communications,” explained Katja Millard, senior director devices at Motorola Solutions.
The introduction of the MXP600 will help agencies to flexibly evolve their mission-critical solutions while taking full advantage of the benefits of secure radio voice communications:
- Be clearly heard in the noisiest environments. The MXP600 uses intelligent microphone technology to suppress background noise and has a maximum loudness that is around four times louder than a typical smartphone. When operating in windy conditions, the device automatically uses the loudspeaker as an additional microphone for optimal wind noise mitigation. When multiple radios are in close proximity, the MXP600 automatically eliminates acoustic feedback to allow for effective communication.
- Radically accelerate device management to keep frontline workers in the field. Over-The-Air-Programming (OTAP) makes it possible for radios to be updated on-the-go and within minutes, avoiding the time, logistics and costs involved with traditional radio programming. OTAP is fast, secure and convenient to maximize the productivity of frontline workers and help to keep them in the field.
- Flexible collaboration. Use your radio in the way that suits you best, with a smartphone app for scrolling through talkgroups, sending secure messages and discreet radio communication when you need it. The new M-RadioControl app offers a flexible way for smartphones to work alongside the MXP600. The NFC chip embedded in the MXP600 makes pairing quick and easy, while Bluetooth 5.0 means the wireless connection between radio, smartphone and other devices remains secure.
The MXP600 integrates the technologies emergency services rely upon to focus on their mission to keep the community safe.
Videos
Adaptive Mission-Critical Audio
Designed and Tested for Extreme Conditions
Frontline Safety Today And Tomorrow
Access a media kit with videos and images here .
About Motorola Solutions
Motorola Solutions is a global leader in mission-critical communications and analytics. Our technology platforms in mission-critical communications, command centre software, video security & analytics, bolstered by managed & support services, make communities safer and help businesses stay productive and secure. At Motorola Solutions, we are ushering in a new era in public safety and security. Learn more at www.motorolasolutions.com .
Follow @MotoSolutions on Twitter
Follow @MotorolaSolutions on Instagram
Follow @MotorolaSolutions on LinkedIn
Like @MotorolaSolutions on Facebook
MOTOROLA, MOTOROLA SOLUTIONS and the Stylized M Logo are trademarks or registered trademarks of Motorola Trademark Holdings, LLC and are used under license. All other trademarks are the property of their respective owners. ©2020 Motorola Solutions, Inc. All rights reserved.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201027005282/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom